Shares of Ignyta Inc. (NASDAQ:RXDX) rose 2.1% on Friday . The company traded as high as $5.78 and last traded at $5.72, with a volume of 112,857 shares. The stock had previously closed at $5.60.

RXDX has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Ignyta from a “buy” rating to a “hold” rating in a report on Friday, March 18th. Cantor Fitzgerald restated a “buy” rating on shares of Ignyta in a report on Thursday, April 7th. Piper Jaffray Cos. restated an “overweight” rating and issued a $32.00 price objective on shares of Ignyta in a report on Monday, April 18th. Jefferies Group restated a “buy” rating and issued a $20.00 price objective on shares of Ignyta in a report on Monday, April 18th. Finally, Leerink Swann restated a “buy” rating on shares of Ignyta in a report on Thursday, May 12th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $18.07.

The firm’s market capitalization is $238.21 million. The firm’s 50-day moving average price is $5.81 and its 200 day moving average price is $7.44.

Ignyta (NASDAQ:RXDX) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.11. On average, analysts expect that Ignyta Inc. will post ($2.72) EPS for the current fiscal year.

In other Ignyta news, Director Alexander W. Casdin bought 232,000 shares of Ignyta stock in a transaction dated Wednesday, May 4th. The shares were purchased at an average cost of $6.25 per share, for a total transaction of $1,450,000.00. Following the acquisition, the director now directly owns 100,000 shares in the company, valued at approximately $625,000. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.